ICE 4 (Deutsche Bahn)

Essentium Helps Deutsche Bahn Expand Additive Manufacturing for Faster Train Maintenance

Retrieved on: 
Wednesday, September 20, 2023

AUSTIN, Texas, Sept. 20, 2023 /PRNewswire/ -- Essentium, Inc., a worldwide leader in industrial additive manufacturing (AM), today announced Deutsche Bahn (DB), the national railway company of Germany, has certified the use of Essentium High Speed Extrusion (HSE™) 3D Printing Platform located in Neumunster and high-performance materials for 3D printed train parts and tools. Essentium's 3D printing technology, including flame-retardant Essentium 9085 and HTN-CF25 thermoplastics, has been tested to demonstrate that it complies with the AM Standard ISO/ASTM 52920:2023 and ISO 52920. Essentium's AM solutions will allow DB to increase the availability of its fleet through fast and efficient replacement of parts and tools.

Key Points: 
  • By leveraging Essentium's AM technology, DB aims to overcome supply chain issues and raw materials shortages for obsolete parts.
  • The Essentium HSE 3D Printing Platform in Neumunster and materials will help Deutsche Bahn enhance delivery speed and lower costs by creating low-run parts on demand rather than mass manufacturing and storing vast quantities.
  • Said Blake Teipel, Ph.D., CEO of Essentium: "A lot of people still wonder if additive is ready for prime time.
  • Deutsche Bahn, which is 3D printing tens of thousands of replacement parts for its trains, proves it is.

Valneva’s Inactivated COVID-19 Vaccine Candidate Shown to Neutralize Omicron Variant

Retrieved on: 
Wednesday, January 19, 2022

100% of tested serum samples presented neutralizing antibodies against the ancestral virus and Delta variant, and 87% against the Omicron variant

Key Points: 
  • 100% of tested serum samples presented neutralizing antibodies against the ancestral virus and Delta variant, and 87% against the Omicron variant
    Saint Herblain (France), January 19, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced results from an initial laboratory study demonstrating that serum antibodies induced by three doses of Valnevas inactivated COVID-19 vaccine candidate, VLA2001, neutralize the Omicron variant.
  • All 30 samples (100%) presented neutralizing antibodies against the ancestral virus and Delta variant, and 26 samples (87%) presented neutralizing antibodies against the Omicron variant.
  • The mean fold reduction of neutralization relative to the ancestral virus was 2.7-fold for Delta and 16.7-fold for Omicron.
  • VLA2001 is produced on Valnevas established Vero-cell platform, leveraging the manufacturing technology for Valnevas licensed Japanese encephalitis vaccine, IXIARO.